SHIP1 inhibits cell growth, migration, and invasion in non‑small cell lung cancer through the PI3K/AKT pathway

  • Authors:
    • Qiaofen Fu
    • Yuhui Huang
    • Chunlei Ge
    • Zhen Li
    • Hui Tian
    • Qiaolin Li
    • Hongshuai Li
    • Ruilei Li
    • Xingyu Tao
    • Yuanbo Xue
    • Ying Wang
    • Guanqin Yang
    • Weiyi Fang
    • Xin Song
  • View Affiliations

  • Published online on: January 30, 2019     https://doi.org/10.3892/or.2019.6990
  • Pages: 2337-2350
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Src homology 2‑containing inositol‑5'‑phosphatase 1 (SHIP1) serves a vital role in the occurrence and development of hematological tumors, but there is limited knowledge regarding the role of SHIP1 in various solid tumors, including lung cancer. In the present study, the aim was to investigate the expression and functional mechanisms of SHIP1 in non‑small cell lung cancer (NSCLC). The Gene Expression Omnibus database demonstrated that SHIP1 had low expression in NSCLC. Further studies using fresh tissues and cell lines also confirmed this observation. Biological function analyses revealed that SHIP1 overexpression notably suppressed cell growth, migration and invasion in vitro and in vivo in NSCLC. Mechanistic analyses indicated that SHIP1 inactivated the phosphoinositide 3‑kinase (PI3K)/AKT pathway to suppress signals associated with the cell cycle and epithelial‑mesenchymal transition. In clinical specimens, reduced SHIP1 is an unfavorable factor and is negatively associated with the T classification, N classification and clinical stage. Furthermore, patients with low SHIP1 levels exhibited reduced survival rate, compared with patients with high levels of the protein. Notably, the promoter of the SHIP1 gene lacks CpG islands, and the suppression of SHIP1 expression is not associated with epidermal growth factor receptor or Kirsten rat sarcoma mutations. Thus, the present study demonstrated that SHIP1 inhibits cell growth, migration and invasion in NSCLC through the PI3K/AKT pathway. Additionally, reduced SHIP1 expression may be an unfavorable factor for NSCLC.
View Figures
View References

Related Articles

Journal Cover

April-2019
Volume 41 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fu Q, Huang Y, Ge C, Li Z, Tian H, Li Q, Li H, Li R, Tao X, Xue Y, Xue Y, et al: SHIP1 inhibits cell growth, migration, and invasion in non‑small cell lung cancer through the PI3K/AKT pathway. Oncol Rep 41: 2337-2350, 2019
APA
Fu, Q., Huang, Y., Ge, C., Li, Z., Tian, H., Li, Q. ... Song, X. (2019). SHIP1 inhibits cell growth, migration, and invasion in non‑small cell lung cancer through the PI3K/AKT pathway. Oncology Reports, 41, 2337-2350. https://doi.org/10.3892/or.2019.6990
MLA
Fu, Q., Huang, Y., Ge, C., Li, Z., Tian, H., Li, Q., Li, H., Li, R., Tao, X., Xue, Y., Wang, Y., Yang, G., Fang, W., Song, X."SHIP1 inhibits cell growth, migration, and invasion in non‑small cell lung cancer through the PI3K/AKT pathway". Oncology Reports 41.4 (2019): 2337-2350.
Chicago
Fu, Q., Huang, Y., Ge, C., Li, Z., Tian, H., Li, Q., Li, H., Li, R., Tao, X., Xue, Y., Wang, Y., Yang, G., Fang, W., Song, X."SHIP1 inhibits cell growth, migration, and invasion in non‑small cell lung cancer through the PI3K/AKT pathway". Oncology Reports 41, no. 4 (2019): 2337-2350. https://doi.org/10.3892/or.2019.6990